44 results on '"Grancha S"'
Search Results
2. Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors
3. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance
4. Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010
5. Management of bleeding disorders: basic science
6. Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates
7. Room temperature, long-term stability of high-purity FVIII/VWF concentrate Fanhdi*: 05 PO 89
8. Comparison of the rate of activation of human and recombinant FIX concentrates in vitro: 05 PO 87
9. Kinetics of in vitro activation of Factor X by human, full-length recombinant and B-domain depleted recombinant FVIII: 05 PO 88
10. High purity human factor IX concentrate for management of haemophilia B: stability study after reconstitution
11. Self project: follow up of long-term stability studies of lyophilized single donor cryoprecipitate
12. Albumin function in acute-on-chronic liver failure (ACLF): Effect of plasma exchange with albumin 5% (PE-A5%)
13. CROSS-SECTIONAL CHARACTERIZATION OF ALBUMIN GLYCATION STATE IN CEREBROSPINAL FLUID AND PLASMA FROM ALZHEIMER’S DISEASE PATIENTS
14. Neutralizing capacity of inhibitors onFVIIIis lower for naturalFVIII/VWFcomplex than for isolatedFVIII:in vitrocomparative study in eleven different therapeuticFVIIIconcentrates
15. THU-260 - Albumin function in acute-on-chronic liver failure (ACLF): Effect of plasma exchange with albumin 5% (PE-A5%)
16. Native plasma‐derivedFVIII/VWFcomplex has lower sensitivity toFVIIIinhibitors than the combination of isolatedFVIIIandVWFproteins. Impact on Bethesda assay titration ofFVIIIinhibitors
17. Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion
18. Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/ VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates.
19. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease
20. Understanding FVIII/VWF complex – report from a symposium of XXIX WFH meeting 2010
21. ALTERED EXPRESSION OF PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 IN PLACENTAS FROM PREGNANT-WOMEN WITH PREECLAMPSIA AND/OR INTRAUTERINE PETAL GROWTH-RETARDATION
22. COLLAGEN AFFINITY TO VON WILLEBRAND FACTOR CONTAINED IN A THERAPEUTIC FVIII/VWF CONCENTRATE EVALUATED BY SURFACE PLASMON RESONANCE
23. EVALUATION BY SURFACE PLASMON RESONANCE OF VWF EFFECT ON MONOCLONAL ANTIBODY DIRECTED TO FVIII LIGHT CHAIN REACTIVITY
24. Plasminogen Activator Inhibitor-1 (PAI-1) Promoter 4G/5G Genotype and Increased PAI-1 Circulating Levels in Postmenopausal Women with Coronary Artery Disease
25. Detailed localization of type-1 plasminogen activator inhibitor mRNA expression and antigen in atherosclerotic plaque on human coronary artery
26. 108 Relationship between PAI-1 promoter polymorphism and PAI-1 circulating levels in postmenopausal women with coronary artery disease (CAD)
27. Fibrinolytic system and reproductive process with special reference to fibrinolytic failure in pre-eclampsia
28. Altered expression of plasminogen activator inhibitor type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation
29. Evaluation of plasminogen activators and plasminogen activator inhibitors in plasma and amniotic fluid in pregnancies complicated with intrauterine fetal growth retardation.
30. Plasma-derived FVIII/VWF complex shows higher protection against inhibitors than isolated FVIII after infusion in haemophilic patients: A translational study.
31. Characterization of antibodies in human immunoglobulin products from different regions worldwide.
32. Increased Albumin Oxidation in Cerebrospinal Fluid and Plasma from Alzheimer's Disease Patients.
33. Human mesenchymal stem cells maintain their phenotype, multipotentiality, and genetic stability when cultured using a defined xeno-free human plasma fraction.
34. The burden of inhibitors in haemophilia patients.
35. Neutralizing capacity of inhibitors on FVIII is lower for natural FVIII/VWF complex than for isolated FVIII: in vitro comparative study in eleven different therapeutic FVIII concentrates.
36. Effect of temperature on plasma freezing under industrial conditions.
37. PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects.
38. Factor V Leiden and antibodies against phospholipids and protein S in a young woman with recurrent thromboses and abortion.
39. Lipoprotein(a) levels and isoforms and fibrinolytic activity in postmenopause--influence of hormone replacement therapy.
40. Abnormal expression of type 1 plasminogen activator inhibitor and tissue factor in severe preeclampsia.
41. Activated protein C resistance phenotype in patients with antiphospholipid antibodies.
42. Decreased expression of PAI-2 mRNA and protein in pregnancies complicated with intrauterine fetal growth retardation.
43. Abnormal expression of plasminogen activator inhibitors in patients with gestational trophoblastic disease.
44. The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in postmenopausal status.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.